BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Authors » Jim Stommen

Articles by Jim Stommen

The MDD Interview: Wellsense helping caregivers to ease patients' sore points

March 28, 2013
By Jim Stommen

Huge potential markets await Actium if new technology is okayed

March 21, 2013
By Jim Stommen

The MDD Interview: Investor has a more personal stake in cancer drug-delivery company

March 14, 2013
By Jim Stommen

Gigantic jury award in first J&J hip implant case is breathtaking as an initial benchmark

March 13, 2013
By Jim Stommen
Chilling. It isn’t often that a bit of news is a perfect fit to that one-word description, but the recent decision by a Los Angeles jury in the first case to be decided pitting Johnson & Johnson (J&J; New Brunswick, New Jersey) against what is a cast of thousands of litigants is nothing short of that. Oh sure, there’s the usual post-decision posturing by the company per appealing the $8.3 million-plus jury award, but c’mon folks, the implications of this case for the medical-products giant – and truly for all other companies trying to do business in the med-tech space...
Read More

The MDD Interview: 'Upstarts' push their way up list of life sciences centers

March 7, 2013
By Jim Stommen
Jones Lang LaSalle is a global financial and professional services firm specializing in commercial real estate services and investment management, with offices in 70 countries serving the real estate needs of a broad list of clients. It produces an annual Life Sciences Cluster Report that covers major global markets with a strong or quickly growing life sciences presence. The U.S. section of this year's report once again featured a ranking of metropolitan areas and this year added a ranking scorecard of the 50 U.S. states and the District of Columbia.
Read More

On Open Innovation, e-Zassi holds a key for device firms

March 1, 2013
By Jim Stommen
Like most entrepreneurs, Peter von Dyck can get pretty evangelistic when he starts talking about his newest idea and newest company. But that company, e-Zassi (Fernandina Beach, Florida), is somewhat different than most start-ups. While it's true that companies are built on ideas, e-Zassi is built on the generating of ideas – that is, making it easier and more efficient to get outside ideas flowing into other companies.
Read More

The MDD Interview: In ranking life science clusters, firm focuses on variety of factors

Feb. 28, 2013
By Jim Stommen
Jones Lang LaSalle is a global financial and professional services firm specializing in commercial real estate services and investment management. It produces an annual Life Sciences Cluster Report that covers major global markets with a strong or quickly growing life sciences presence. The U.S. section of this year's report once again featured a ranking of metropolitan areas and this year added ranking scorecard of the 50 U.S. states and the District of Columbia.
Read More

The MDD Interview: 'Three layers of protection' are keys to a safer sport, says Duma

Feb. 21, 2013
By Jim Stommen
Stefan Duma, PhD, is professor and head of the Department of Biomedical Engineering in the College of Engineering at Virginia Tech (Blacksburg, Virginia). The founding director of Virginia Tech's Center for Injury Biomechanics, he is internationally recognized for his studies in injury biomechanics and traumatic brain injury and part of the national debate over how to protect young athletes from concussions.
Read More

The MDD Interview: As season ends, researchers still huddling on concussion studies

Feb. 14, 2013
By Jim Stommen
Stefan Duma, PhD, is professor and head of the Department of Biomedical Engineering in the College of Engineering at Virginia Tech (Blacksburg, Virginia). The founding director of Virginia Tech's Center for Injury Biomechanics, he is internationally recognized for his studies in injury biomechanics and traumatic brain injury and part of the national debate over how to protect young athletes from concussions.
Read More

The MDD Interview: Lombard: Firm's goal is to impact the cost of healthcare overall

Feb. 7, 2013
By Jim Stommen
Dr. Jay Lombard, a neurologist, is the co-founder and chief scientific officer of Genomind (Chalfont, Pennsylvania), a company focused on improving the lives of patients with psychiatric and neurological conditions through biomarker discovery. Lombard has researched and developed several novel therapeutic interventions to treat depression, dementia, and autism.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 31 32 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing